Fierce Biotech May 28, 2024
Not satisfied with just one new immunology deal this month, Johnson & Johnson is plunking down $1.25 billion in cash to scoop up rights to Numab Therapeutics’ phase 2-ready atopic dermatitis bispecific antibody.
The healthcare giant is picking up NM26, which is on the cusp of entering midstage trials. The therapy is currently in development for atopic dermatitis (AD), but J&J has its sights set on other inflammatory skin diseases.
Details of the transaction in a Tuesday release were slim, besides the eye-popping all-cash payment of $1.25 billion to be paid to Numab for global rights to the drug. J&J is not buying the biotech itself—just the drug rights. Closing is expected in the second half of the year.
But...
Today's Sponsors
Today's Sponsor